# US 10,308,681 B2 · Pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the peptide having the ability to inhibit angiotensin-1 converting enzyme as an active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,681 B2
- Document ID: US10308681B2
- Status: Granted
- Kind: B2
- Application number: 15/856,926
- Filed: 2017-12-28
- Published: 2018-06-21
- Granted: 2019-06-04
- Earliest claimed: 2012-08-24
- Assignees: University-Industry Cooperation Group of Kyung Hee University; Industry-Academic Cooperation Foundation Gyeongsang National University
- Applicants: University-Industry Cooperation Group of Kyung Hee University; Industry-Academic Cooperation Foundation Gyeongsang National University
- Inventors: Se-Young Choung; Yeung Joon Choi
- Web page: https://patentgrep.com/patent/US10308681B2

## CPC

- C07K 5/06086: {with the first amino acid being basic}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- C07K 5/06052: {Val-amino acid}
- C07K 5/0606: {the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr}
- C07K 5/06069: {Ser-amino acid}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/06165: {and Pro-amino acid; Derivatives thereof}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K 5/0823: {and Pro-amino acid; Derivatives thereof}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a peptide separated from the fraction of oyster enzyme hydrolysate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrolysate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrolysate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease.

## Claims

### Claim 1

A method for treating cardiovascular disease comprising the step of administering a fraction of an oyster enzyme hydrolysate containing at least one peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2 and SEQ ID NOs. 5-11 to a subject having cardiovascular disease.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fraction of the oyster enzyme hydrolysate has a molecular weight up to 10 kD.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cardiovascular disease is one or more diseases selected from the group consisting of hypertension, heart disease, stroke, thrombosis, angina pectoris, heart failure, myocardial infarction, atherosclerosis, and arteriosclerosis.